Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GRM3 | Q14832 | 3/20 | 0.50 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1909511 | 0.87 | MMP3 (0.50) | GAASMN1; SMN2TSHRRECQLHPGD | |
| SCHEMBL1109146 | 0.82 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL12064387 | 0.82 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL399384 | 0.82 | HSD11B1 (0.50) | HSD11B1 | |
| SCHEMBL1909368 | 0.80 | NPC1 (0.55) | SMN1; SMN2TSHRRECQLHPGDSLC18A3 | |
| SCHEMBL4001868 | 0.77 | ALDH1A1 (0.74) | GAASMN1; SMN2TSHRRECQLHPGD | |
| SCHEMBL4001869 | 0.77 | ALDH1A1 (0.74) | GAASMN1; SMN2TSHRRECQLHPGD | |
| SCHEMBL27011217 | 0.77 | ALDH1A1 (0.74) | GAASMN1; SMN2TSHRRECQLHPGD | |
| SCHEMBL401215 | 0.77 | S1PR1 (0.46) | TSHRALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL13753517 | 0.74 | HPGD (0.71) | GAASMN1; SMN2HPGDPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | GAA 79/4885SMN1; SMN2 2296/4885TSHR 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.